{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:39:58Z","timestamp":1793741998406,"version":"4.6.1"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004835","name":"Zhejiang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA0909900"],"award-info":[{"award-number":["2021YFA0909900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52173142"],"award-info":[{"award-number":["52173142"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072650"],"award-info":[{"award-number":["82072650"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2021C03121"],"award-info":[{"award-number":["2021C03121"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bioactmat.2023.11.002","type":"journal-article","created":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T11:05:29Z","timestamp":1700996729000},"page":"377-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Rationally designed approaches to augment CAR-T therapy for solid tumor treatment"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-6725","authenticated-orcid":false,"given":"Chaojie","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4173-1793","authenticated-orcid":false,"given":"Yang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxizi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioactmat.2023.11.002_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib2","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib4","doi-asserted-by":"crossref","first-page":"24275","DOI":"10.1073\/pnas.1903854116","article-title":"Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice","volume":"116","author":"Mulazzani","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"4","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2\u2013chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202009489","article-title":"Delivery techniques for enhancing CAR T cell therapy against solid tumors","volume":"31","author":"Fu","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5474602","article-title":"CAR T cell therapy: a game changer in cancer treatment","author":"Alm\u00e5sbak","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib15","first-page":"780","article-title":"Engineering-enhanced CAR T cells for improved cancer therapy","volume":"2","author":"Milone","year":"2021","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib16","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib17","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.91.10.4318","article-title":"Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells","volume":"91","author":"Moritz","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3567","article-title":"Human memory T cells: generation, compartmentalization and homeostasis","volume":"14","author":"Farber","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk1900","article-title":"T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib26","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T \u2013 and a side order of IgG, to go? \u2013 Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","article-title":"Designing chimeric antigen receptors to effectively and safely target tumors","volume":"33","author":"Jensen","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","article-title":"Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma","volume":"9","author":"Yi","year":"2018","journal-title":"Mol. Ther. - Methods & Clin. Dev."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib31","first-page":"6938","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3\u03b6 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J.I."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.12216","article-title":"CD3\u03b6-based chimeric antigen receptors mediate T cell activation via cis - and trans -signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy","volume":"175","author":"Bridgeman","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib33","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1182\/blood-2004-09-3737","article-title":"Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation","volume":"105","author":"Friedmann-Morvinski","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib35","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"IJMS"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/cdd.2011.156","article-title":"Granzymes, cytotoxic granules and cell death: the early work of Dr. Jurg Tschopp","volume":"19","author":"Trapani","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.cdd.4402244","article-title":"Mechanisms of granule-dependent killing","volume":"15","author":"Cullen","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib38","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1158\/0008-5472.CAN-14-0079","article-title":"Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFN\u03b3","volume":"74","author":"Textor","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","article-title":"CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape","volume":"11","author":"Rodriguez-Garcia","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib40","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib41","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell\u2013derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib42","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib43","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib44","doi-asserted-by":"crossref","first-page":"eabi5781","DOI":"10.1126\/sciadv.abi5781","article-title":"Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors","volume":"7","author":"Cadilha","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib45","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ymthe.2019.10.010","article-title":"The vascular disrupting agent CA4P improves the antitumor efficacy of CAR-T cells in preclinical models of solid human tumors","volume":"28","author":"Deng","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib49","article-title":"Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib50","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/pharmaceutics13070940","article-title":"Recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems for cancer treatment","volume":"13","author":"Zhu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib51","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1039\/D2BM01593E","article-title":"Engineered bacteria for augmented in situ tumor vaccination","volume":"11","author":"Shen","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003760","article-title":"Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment","volume":"10","author":"Guo","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR\u2013T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib54","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib55","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jconrel.2022.11.041","article-title":"Cell delivery devices for cancer immunotherapy","volume":"353","author":"Wen","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib56","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg5841","article-title":"Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma","volume":"7","author":"Ogunnaike","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41551-019-0486-0","article-title":"Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours","volume":"4","author":"Coon","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib59","doi-asserted-by":"crossref","first-page":"nwab172","DOI":"10.1093\/nsr\/nwab172","article-title":"Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy","volume":"9","author":"Li","year":"2022","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz3223","article-title":"Chimeric antigen receptor signaling: functional consequences and design implications","volume":"6","author":"Lindner","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib61","doi-asserted-by":"crossref","unstructured":"Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, Huang M, Meng L, He X, Zhu H, Gao S, Zhang N, Jing R, Sun J, Wang H, Hui E, Wong CC, Xu C. Multiple Signaling Roles of CD3\u03b5 and Its Application in CAR-T Cell Therapy, Cell. 182 (2020) 855-871.","DOI":"10.1016\/j.cell.2020.07.018"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/hum.2009.122","article-title":"4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies","volume":"21","author":"Tammana","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell\u2013mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib66","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omto.2021.03.014","article-title":"Secretion of bispecific protein of anti-PD-1 fused with TGF-\u03b2 trap enhances antitumor efficacy of CAR-T cell therapy","volume":"21","author":"Chen","year":"2021","journal-title":"Mol. Ther. - Oncolytics"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib68","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib69","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-011-1155-7","article-title":"Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor","volume":"61","author":"Waickman","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib70","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib71","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101641","article-title":"Nanomodulators targeting tumor-resident immunosuppressive cells: mechanisms and recent updates","volume":"47","author":"Shen","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib74","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib75","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M","article-title":"Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer","volume":"83","author":"Kammula","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An orthogonal IL-2 and IL-2R\u03b2 system drives persistence and activation of CAR T cells and clearance of bulky lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib79","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib80","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","article-title":"Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy","volume":"29","author":"Rezaei","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202370197","article-title":"Inhibition of tumor metastasis by liquid\u2010nitrogen\u2010shocked tumor cells with oncolytic viruses infection","volume":"35","author":"Wu","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib82","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib83","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.ymthe.2021.02.004","article-title":"Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity","volume":"29","author":"McKenna","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib84","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nbt.3104","article-title":"Biopolymer implants enhance the efficacy of adoptive T-cell therapy","volume":"33","author":"Stephan","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib85","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","article-title":"Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets","volume":"5","author":"Hu","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib86","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","article-title":"Clinical implications of intratumor heterogeneity: challenges and opportunities","volume":"98","author":"Ram\u00f3n","year":"2020","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib87","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2018.03.002","article-title":"Driving CARs on the uneven road of antigen heterogeneity in solid tumors","volume":"51","author":"Chen","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib88","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib89","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib90","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib91","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib92","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T CellMediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib94","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib95","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib96","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41551-022-00875-5","article-title":"CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers","volume":"6","author":"Jin","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib97","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41589-021-00932-1","article-title":"Engineering CAR-T cells to activate small-molecule drugs in situ","volume":"18","author":"Gardner","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib98","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41589-021-00933-0","article-title":"CAR-T cells SEAK help from enzymes","volume":"18","author":"Vincent","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib99","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","article-title":"The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function","volume":"184","author":"Johnson","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib101","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrc2934","article-title":"Engineering the perfect (bacterial) cancer therapy","volume":"10","author":"Forbes","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib102","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41551-021-00772-3","article-title":"Enhancing the tropism of bacteria via genetically programmed biosensors","volume":"6","author":"Chien","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib103","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.add7034","article-title":"Probiotic-guided CAR-T cells for solid tumor targeting","volume":"382","author":"Vincent","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib104","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib106","first-page":"1","article-title":"Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies","author":"Sun","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib107","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib108","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib109","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.14680","article-title":"Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy","volume":"181","author":"Mei","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib110","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib111","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Oosterwijk","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib112","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fimmu.2020.00326","article-title":"Emerging approaches for regulation and control of CAR T cells: a mini review","volume":"11","author":"Brandt","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib113","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib115","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib116","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","article-title":"Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control","volume":"5","author":"Miller","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib117","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","article-title":"Control of the activity of CAR-T cells within tumours via focused ultrasound","volume":"5","author":"Wu","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib118","article-title":"Engineering light-controllable CAR T cells for cancer immunotherapy, Sci","volume":"6","author":"Huang","year":"2020","journal-title":"Adv"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib119","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","article-title":"Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety","volume":"16","author":"Nguyen","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib120","first-page":"415","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib121","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib123","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib124","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","article-title":"The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells","volume":"211","author":"Bachmann","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib125","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib126","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/ijms21020515","article-title":"Finding the keys to the CAR: identifying novel target antigens for T cell redirection immunotherapies","volume":"21","author":"Abbott","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib127","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40364-020-00190-8","article-title":"Biomarkers in individualized management of chimeric antigen receptor T cell therapy","volume":"8","author":"Du","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib129","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-021-04061-6","article-title":"Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs","volume":"599","author":"Yarmarkovich","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib131","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib132","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/hum.2017.254","article-title":"CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications","volume":"29","author":"K\u00f6hl","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib133","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib134","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib135","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for \u201cuniversal\u201d T-cell based immunotherapy: T-cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib136","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib137","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib138","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR\u2013Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib139","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib140","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","article-title":"Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells","volume":"40","author":"Agarwalla","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib141","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw5096","article-title":"Imaging CAR T cell therapy with PSMA-targeted positron emission tomography","volume":"5","author":"Minn","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib142","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.omto.2021.06.006","article-title":"Imaging CAR T-cell kinetics in solid tumors: translational implications","volume":"22","author":"Skovgard","year":"2021","journal-title":"Mol. Ther. - Oncolytics"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib143","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib144","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib145","first-page":"17","article-title":"GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and","volume":"1","author":"Wang","year":"2020","journal-title":"Preserve Vision"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113138","article-title":"Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy","volume":"42","author":"Xu","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib147","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41565-022-01098-0","article-title":"A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy","volume":"17","author":"Liu","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib148","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib149","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2023.11.002_bib150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioactmat.2023.11.002_bib151","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1038\/emm.2014.114","article-title":"Understanding of molecular mechanisms in natural killer cell therapy","volume":"47","author":"Yoon","year":"2015","journal-title":"Exp. Mol. Med."}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X23003511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X23003511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:47:14Z","timestamp":1762786034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X23003511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":151,"alternative-id":["S2452199X23003511"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2023.11.002","relation":{},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationally designed approaches to augment CAR-T therapy for solid tumor treatment","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2023.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}